


THAT WHICH IS CLAIMED IS:

1. A compound according to Formula I:



wherein:

R₁, R₂, R₃ and R₄ are each independently selected from the group consisting of H, alkyl, alkoxy, halide, and alkylhalide groups;


R₅ is H, alkyl or aryl;

R₆ is H, alkyl, aryl, or NR₇R₈, wherein R₇ and R₈ are each independently selected from the group consisting of H, alkyl and aryl; and

X is O, S or NR₉, wherein R₉ is H or alkyl.

2. The compound according to Claim 1, wherein R₁ and R₂ are each an H.
3. The compound according to Claim 1, wherein R₁ and R₂ are each an H and R₃ and R₄ are each lower alkyls.
4. The compound according to Claim 1, wherein R₃ and R₄ are each a halide.
5. The compound according to Claim 1, wherein R₃ and R₄ are each alkoxy.
6. The compound according to Claim 1, wherein R₃ and R₄ are each alkyl halides.
7. The compound according to Claim 1, wherein R₅ is an H, R₆ is a NR₇R₈, and R₇ and R₈ are each an H.
8. The compound according to Claim 1, wherein R₆ is a pyridyl.

9. The compound according to Claim 1, wherein R_6 is a substituted pyridyl.
10. The compound according to Claim 1, wherein R_6 is a quinolinyl.
11. A pharmaceutical composition comprising a compound according to Formula



wherein:

- R_1 , R_2 , R_3 and R_4 are each independently selected from the group consisting of H, alkyl, alkoxy, halide, and alkylhalide groups;
- R_5 is H, alkyl or aryl;
- R_6 is H, alkyl, aryl, or NR_7R_8 , wherein R_7 and R_8 are each independently selected from the group consisting of H, alkyl and aryl; and
- X is O, S or NR_9 , wherein R_9 is H or alkyl;
- in a pharmaceutically acceptable carrier.


12. The pharmaceutical composition of Claim 11, wherein the composition is formulated for parenteral administration.

13. The pharmaceutical composition of Claim 11, wherein the composition is formulated for oral administration.

14. The pharmaceutical composition of Claim 11, wherein the composition is formulated for topical administration.

15. A process for preparing a pharmaceutical composition comprising formulating the compound of the formula (I) according to claim 1 and optionally a pharmaceutically utilizable carrier.

16. A method of treating a microbial infection in a subject in need of such treatment, wherein the microbial infection is caused by a microorganism selected from the group consisting of *Mycobacterium tuberculosis*, *Trypanosoma* spp., *Candida albicans*, *Aspergillus* spp., *Cryptosporidium parvum*, *Giardia lamblia*, *Plasmodium* spp., *Pneumocystis carinii*, *Toxoplasma gondii*, *Fusarium solani*, and *Cryptococcus neoformans*, said method comprising administering to the subject a compound according to Formula I or a pharmaceutically acceptable salt thereof:



wherein:

wherein R₁, R₂, R₃ and R₄ are each independently selected from the group consisting of H, alkyl, alkoxy, halide, and alkylhalide groups;

R₅ is H, alkyl or aryl;

R₆ is H, alkyl, aryl, or NR₇R₈, wherein R₇ and R₈ are each independently selected from the group consisting of H, alkyl and aryl; and

X is O, S or NR₉, wherein R₉ is H or alkyl.

17. The method according to Claim 16, wherein the compound is administered parenterally.

18. The method according to Claim 16, wherein the compound is administered orally.

19. The method according to Claim 16, wherein the compound is administered topically.